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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure that 
enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results 
of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Paraguayan Spanish 
language. The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating 
centre was asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive 
patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical 
validation phase explored descriptive statistics and the psychometric issues of the JAMAR: the 3 Likert assumptions, floor/
ceiling effects, internal consistency, Cronbach’s alpha, interscale correlations, and construct validity (convergent and discri-
minant validity). A total of 51 JIA patients (2% systemic, 27.4% oligoarticular, 37.2% RF negative polyarthritis, 33.4% other 
categories) and 100 healthy children, were enrolled. The JAMAR components discriminated well healthy subjects from JIA 
patients. Notably, there was no significant difference between healthy subjects and their affected peers in the school-related 
problem variable. All JAMAR components revealed good psychometric performances. In conclusion, the Paraguayan Spanish 
version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for use both in routine clinical 
practice and clinical research.
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Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Paraguayan Spanish parent, child/adult ver-
sion of the Juvenile Arthritis Multidimensional Assessment 
Report (JAMAR) [1] in patients with juvenile idiopathic 
arthritis (JIA). The JAMAR assesses the most relevant 
Rheumatology
INTERNATIONAL 
The local members of the Paediatric Rheumatology International 
Trials Organisation (PRINTO) participating in the project 
are listed in the dedicated tables no. 2 and 3 of “https ://doi.
org/10.1007/s0029 6-018-3944-1 / Cross-cultural adaptation 
and psychometric evaluation of the Juvenile Arthritis 
Multidimensional Assessment Report (JAMAR) in 54 languages 
across 52 countries: review of the general methodology”.
 * Zoilo Morel Ayala 
 zoiloma@hotmail.com
 * Nicolino Ruperto 
 nicolaruperto@gaslini.org
 http://www.printo.it
 Ruben Burgos-Vargas 
 r.burgos.vargas@gmail.com
 Alessandro Consolaro 
 alessandroconsolaro@gaslini.org
 Francesca Bovis 
 francescabovis@gaslini.org
1 Reumatología Pediátrica, Cátedra y Servicio de Pediatría, 
Hospital de Clínicas, Facultad de Ciencias Médicas, 
Universidad Nacional de Asunción, Mariscal Lopez 1102 
Casi Cruzada De La Amistad, San Lorenzo, Paraguay
2 Departamento de Reumatología, Hospital General de 
Mexico, Mexico, Mexico
3 Clinica Pediatrica e Reumatologia, Paediatric Rheumatology 
International Trials Organisation (PRINTO), Istituto 
Giannina Gaslini, Via Gaslini 5, 16147 Genoa, Italy
4 Dipartimento di Pediatria, Università di Genova, Genoa, Italy
S308 Rheumatology International (2018) 38 (Suppl 1):S307–S313
1 3
parent/patient reported outcomes in JIA, including overall 
well-being, functional status, health related quality of life 
(HRQoL), pain, morning stiffness, disease activity/status/
course, articular and extra-articular involvement, drug-
related side effects/compliance and satisfaction with illness 
outcome.
This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organisation (PRINTO) [2] aimed to evaluate the Epide-
miology, Outcome and Treatment of Childhood Arthritis 
(EPOCA) in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Paraguayan Spanish language.
Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified according 
to the ILAR criteria [5, 6] enrolled from September 2012 to 
November 2013. Children were recruited after Ethics Com-
mittee approval and consent from at least one parent.
The JAMAR
The JAMAR [1] includes the following 15 sections:
 1. Assessment of physical function (PF) using 15-items 
in which the ability of the child to perform each task is 
scored as follows: 0 = without difficulty, 1 = with some 
difficulty, 2 = with much difficulty, 3 = unable to do and 
not applicable if it was not possible to answer the ques-
tion or the patient was unable to perform the task due 
to their young age or to reasons other than JIA. The 
total PF score ranges from 0 to 45 and has 3 com-
ponents: PF-lower limbs (PF-LL); PF-hand and wrist 
(PF -HW) and PF-upper segment (PF-US) each scor-
ing from 0 to 15 [7]. Higher scores indicating higher 
degree of disability [8–10];
 2. Rating of the intensity of the patient’s pain on a 
21-numbered circle visual analogue scale (VAS) [11];
 3. Assessment of the presence of joint pain or swelling 
(present/absent for each joint);
 4. Assessment of morning stiffness (present/absent);
 5. Assessment of extra-articular symptoms (fever and 
rash) (present/absent);
 6. Rating of the level of disease activity on a 21-circle 
VAS;
 7. Rating of disease status at the time of the visit (cat-
egorical scale);
 8. Rating of disease course from previous visit (categori-
cal scale);
 9. Checklist of the medications the patient is taking (list 
of choices);
 10. Checklist of side effects of medications;
 11. Report of difficulties with medication administration 
(list of items);
 12. Report of school/university/work problems caused by 
the disease (list of items);
 13. Assessment of HRQoL, through the Physical Health 
(PhH), and Psychosocial Health (PsH) subscales (5 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14];
 14. Rating of the patient’s overall well-being on a 21-num-
bered circle VAS;
 15. A question about satisfaction with the outcome of the 
illness (Yes/No) [15].
The JAMAR is available in three versions, one for parent 
proxy-report (child’s age 2–18), one for child self-report, 
with the suggested age range of 7–18 years, and one for 
adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to international guidelines with 2–3 forward and 
backward translations. In those countries for which the trans-
lation of JAMAR had been already cross-cultural adapted 
in a similar language (i.e. Spanish in South American coun-
tries), only the probe technique was performed. For the 
Paraguayan version of JAMAR, cross-cultural adaptation 
from the Mexican Spanish version was performed. Reading 
comprehension and understanding of the translated question-
naires were tested in a probe sample of ten JIA parents and 
ten patients.
Each participating centre was asked to collect demo-
graphic, clinical data and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy children 
and their parents.
The statistical validation phase explored the descriptive 
statistics and the psychometric issues [16]. In particular, we 
evaluated the following validity components: the first Likert 
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assumption [mean and standard deviation (SD) equivalence]; 
the second Likert assumption or equal item–scale correla-
tions (Pearson r: all items within a scale should contribute 
equally to the total score); third Likert assumption (item 
internal consistency or linearity for which each item of a 
scale should be linearly related to the total score that is 
90% of the items should have Pearson r ≥ 0.4); floor/ceiling 
effects (frequency of items at lower and higher extremes 
of the scales, respectively); internal consistency, measured 
by the Cronbach’s alpha, interscale correlation (the corre-
lation between two scales should be lower than their reli-
ability coefficients, as measured by Cronbach’s alpha); and 
construct validity in its two components: the convergent 
or external validity which examines the correlation of the 
JAMAR sub-scales with the 6 JIA core set variables, with 
the addition of the parent assessment of disease activity 
and pain by the Spearman’s correlation coefficients (r) [17] 
and the discriminant validity, which assesses whether the 
JAMAR discriminates between the different JIA categories 
and healthy children [18]. Test–retest reliability of the Para-
guayan version of the JAMAR was not assessed.
Quantitative data were reported as medians with 1st and 
3rd quartiles and categorical data as absolute frequencies 
and percentages.
The complete Paraguayan Spanish parent and patient ver-
sions of the JAMAR are available upon request to PRINTO.
Results
Cross cultural adaptation
The Paraguayan Spanish JAMAR was fully cross-culturally 
adapted from the Mexican Spanish version.
All 123 lines of the parent version of the JAMAR were 
understood by at least 80% of the 10 parents tested (median 
100%; range 80–100%). All the 120 lines of the patient ver-
sion of the JAMAR were understood by at least 80% of the 
children (median 100%; range 80–100%). Both versions of 
the JAMAR were unmodified after the probe technique.
Demographic and clinical characteristics 
of the subjects
A total of 51 JIA patients and 100 healthy children (total of 
151 subjects), were enrolled at the paediatric rheumatology 
centre of San Lorenzo in Paraguay.
In the 51 JIA subjects, the JIA categories were 2% with 
systemic arthritis, 27.4% with oligoarthritis, 37.2% with RF 
negative polyarthritis, 17.6% with RF positive polyarthritis, 
5.9% with psoriatic arthritis and 9.8% with enthesitis related 
arthritis (Table 1). Notably, none of the enrolled JIA patients 
is affected with undifferentiated arthritis.
A total of 62/151 (41%) subjects had the parent version 
of the JAMAR completed by a parent (51 from parents of 
JIA patients and 11 from parents of healthy children). The 
JAMAR was completed by 55/62 (88.7%) mothers and 7/62 
(11.3%) fathers. The child version of the JAMAR was com-
pleted by all the 151 children aged 7.3 or older.
Discriminant validity
The JAMAR results are presented in Table 1, including 
the scores (median (1st–3rd quartile)) obtained for the PF, 
the PhH, the PsH subscales and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers. However, there was no 
significant difference between healthy subjects and their 
affected peers in the school-related problem variable.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The fol-
lowing results section refers mainly to the parent’s version 
findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
There were no missing results for all JAMAR items, since 
data were collected through a web-based system that did not 
allow to skip answers and input of null values.
The response pattern for both PF and HRQoL was posi-
tively skewed toward normal functional ability and normal 
HRQoL. A reduced number of response choices was used 
for the different HRQoL items (except for items 2, 3 and 4) 
and for all the PF items (except for items 1, 3, 4 and 13).
The mean and SD of the items within a scale were 
roughly equivalent for the PF and for the HRQoL items, 
except for HRQoL item 7 (data not shown). The median 
number of items marked as not applicable was 0% (0%-0%) 
for the PF and for the HRQoL items.
Floor and ceiling effect
The median floor effect was 88.2% (82.4–94.1%) for the PF 
items, 72.5% (72.5–76.5%) for the HRQoL PhH items, and 
62.7% (56.9–62.7%) for the HRQoL PsH items. The median 
ceiling effect was 0% (0–2%) for the PF items, 2% (0%-2%) 
for the HRQoL PhH items, and 0% (0–0%) for the HRQoL 
PsH items. The median floor effect was 64.7% for the pain 
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Table 1  Descriptive statistics (medians, 1st–3rd quartiles or absolute frequencies and %) for the 51 JIA patients
Data related to the JAMAR refers to the 51 JIA patients and to the 11 healthy subjects for whom the questionnaire has been completed by the 
parents
JAMAR Juvenile Arthritis Multidimensional Assessment Report, ESR erythrocyte sedimentation rate, MD Medical Doctor, VAS visual analogue 
scale (score 0–10; 0 = no activity, 10 = maximum activity), LOM limitation of motion, ANA anti-nuclear antibodies, PF physical function (total 
score ranges from 0 to 45), HRQoL Health Related Quality of Life (total score ranges from 0 to 30), PhH Physical Health (total score ranges 
from 0 to 15), PsH Psychosocial Health (total score ranges from 0 to 15)
p values refers to the comparison of the different JIA categories or to JIA versus healthy
*p < 0.05, **p < 0.001, #p < 0.0001
Systemic (N = 1) Oligoarthritis 
(N = 14)
RF − poly-
arthritis (N = 19)
RF + poly-arthri-
tis (N = 9)
Psoriatic arthri-
tis (N = 3)
Enthesitis 
related arthritis 
(N = 5)
All JIA patients 
(N = 51)
Healthy 
(N = 100)
Female 0 (0%) 8 (57.1%) 10 (52.6%) 9 (100%) 1 (33.3%) 1 (20%) 29 (56.9%) 53 (53%)
Age at visit 13.5 (13.5–13.5) 13.7 (11.5–14.6) 15.2 (12.3–16.3) 14.4 (13.9–15.4) 14.1 (12.3–15.7) 11 (10.8–14.1) 14 (12.3–15.4) 12.2 (10–
14.3)**
Age at onset 11.4 (11.4–11.4) 10.7 (7.3–11.8) 12 (6.3–14.1) 11.8 (10.9–13.4) 10.9 (9.5–12.6) 7.1 (6–8.3) 10.9 (7.1–13.2)
Disease duration 2.1 (2.1–2.1) 2.9 (1.6–4.2) 1.9 (1.5–6.5) 2.7 (2–3.1) 1.5 (1.4–6.3) 3.7 (2–6.9) 2.2 (1.5–4.2)
ESR 30 (30–30) 15 (10–22) 16.5 (7–32) 11.5 (10–27.5) 20 (18–25) 20 (17–20) 17 (10–27.5)
MD VAS 0 (0–0) 0 (0–0) 0 (0–1) 0 (0–0) 0 (0–7) 0 (0–1) 0 (0–1)
No. of swollen 
joints
0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–16) 0 (0–0) 0 (0–0)
No. of joints with 
pain
0 (0–0) 0 (0–0) 0 (0–1) 0 (0–0) 0 (0–16) 0 (0–0) 0 (0–0)
No. of joints with 
LOM
0 (0–0) 0 (0–1) 0 (0–3) 0 (0–2) 0 (0–16) 0 (0–1) 0 (0–2)
No. of active joints 0 (0–0) 0 (0–0) 0 (0–1) 0 (0–0) 0 (0–16) 0 (0–0) 0 (0–0)
Active systemic 
features
0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
ANA status 0 (0%) 0 (0%) 1 (5.3%) 2 (22.2%) 0 (0%) 0 (0%) 3 (5.9%)
Uveitis 1 (100%) 1 (7.1%) 1 (5.3%) 1 (11.1%) 0 (0%) 0 (0%) 4 (7.8%)
PF total score 0 (0–0) 0 (0–3) 0 (0–3) 0 (0–2) 0 (0–18) 3 (0–5) 0 (0–3) 0 (0–0)*
Pain VAS 0 (0–0) 0 (0–0.5) 0 (0–2) 0 (0–0) 0 (0–5) 0.5 (0–2.5) 0 (0–2) 0 (0–0)*
Disease activity 
VAS
0 (0–0) 0 (0–0.5) 0 (0–2) 0 (0–0) 0 (0–5) 0.5 (0–2.5) 0 (0–2)
Well-being VAS 0 (0–0) 0 (0–1) 0 (0–2) 0 (0–1) 1 (0–5) 0 (0–4) 0 (0–2)
HRQoL PhH 0 (0–0) 0 (0–2) 0 (0–1) 1 (0–4) 1 (0–8) 1 (0–4) 0 (0–3) 0 (0–0)*
HRQoL PsH 3 (3–3) 2 (0–3) 2 (0–3) 3 (1–4) 0 (0–8) 2 (2–2) 2 (1–3) 0 (0–1)*
HRQoL total score 3 (3–3) 2 (0–4) 2 (1–4) 3 (2–7) 1 (0–16) 2 (2–8) 2 (1–6) 0 (0–1)*
Pain/swell. in > 1 
joint
0 (0%) 2 (14.3%) 6 (31.6%) 2 (22.2%) 1 (33.3%) 1 (20%) 12 (23.5%) 0 (0%)
Morning stiff-
ness > 15 min
0 (0%) 0 (0%) 2 (10.5%) 0 (0%) 0 (0%) 2 (40%) 4 (7.8%)* 0 (0%)
Subjective remis-
sion
0 (0%) 2 (14.3%) 6 (31.6%) 2 (22.2%) 1 (33.3%) 2 (40%) 13 (25.5%)
In treatment 1 (100%) 13 (92.9%) 17 (89.5%) 9 (100%) 3 (100%) 5 (100%) 48 (94.1%)
Reporting side 
effects
0 (0%) 3/13 (23.1%) 3/17 (17.6%) 3 (33.3%) 1 (33.3%) 1 (20%) 11/48 (22.9%)
Taking medication 
regularly
1 (100%) 11/13 (84.6%) 14/17 (82.4%) 8 (88.9%) 3 (100%) 5 (100%) 42/48 (87.5%)
With problems 
attending school
0 (0%) 0 (0%) 1/17 (5.9%) 0 (0%) 0 (0%) 1/4 (25%) 2/46 (4.3%) 0 (0%)
Satisfied with dis-
ease outcome
1 (100%) 9 (64.3%) 12 (63.2%) 7 (77.8%) 2 (66.7%) 2 (40%) 33 (64.7%)
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VAS, 66.7% for the disease activity VAS and 58.8% for the 
well-being VAS. The median ceiling effect was 0% for the 
pain VAS, 0% for the disease activity VAS and 0% for the 
well-being VAS.
Equal item–scale correlations (second Likert 
assumption)
Pearson item–scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 93% of the 
PF items, with the exception of PF item 9, and for 80% of 
the HRQoL items, with the exception of HRQoL items 1 
and 5.
Items internal consistency (third Likert assumption)
Pearson item–scale correlations were ≥ 0.4 for 100% of 
items of the PF and 100% of items of the HRQoL.
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiopathic arthritis, VAS visual analogue scale, PF physical func-
tion, HRQoL Health Related Quality of Life, PhH Physical Health, PsH Psychosocial Health, PF-LL PF-lower limbs, PF-HW PF-hand and wrist, 
PF-US PF-upper segment
Parent (N = 51/62) Child (N = 51/151)
Missing values (1st–3rd quartiles) No missing values No missing values
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 88.2% 90.2%
 HRQoL PhH 72.5% 78.4%
 HRQoL PsH 62.7% 64.7%
 Pain VAS 64.7% 68.6%
 Disease activity VAS 66.7% 70.6%
 Well-being VAS 58.8% 72.5%
Ceiling effect, median
 PF 0.0% 0.0%
 HRQoL PhH 2.0% 0.0%
 HRQoL PsH 0.0% 2.0%
 Pain VAS 0.0% 0.0%
 Disease activity VAS 0.0% 0.0%
 Well-being VAS 0.0% 0.0%
Items with equivalent item–scale correlation 93% for PF, 80% for HRQoL 87% for PF, 90% for HRQoL
Items with item–scale correlation ≥ 0.4 100% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Cronbach’s alpha
 PF-LL 0.93 0.90
 PF-HW 0.92 0.90
 PF-US 0.96 0.94
 HRQoL-PhH 0.90 0.89
 HRQoL-PsH 0.83 0.85
Items with item–scale correlation lower than the Cronbach alpha 87% for PF, 90% for HRQoL 87% for PF, 100% for HRQoL
Spearman correlation with JIA core-set variables, median
 PF 0.7 0.7
 HRQoL PhH 0.6 0.6
 HRQoL PsH 0.4 0.4
 Pain VAS 0.7 0.7
 Disease activity VAS 0.7 0.6
 Well-being VAS 0.7 0.6
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Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.93 for PF-LL, 0.92 for PF-HW, 
0.96 for PF-US. Cronbach’s alpha was 0.90 for HRQoL-
PhH and 0.83 for HRQoL-PsH.
Interscale correlation
The Pearson correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha 
for all the items (except for PF items 7 and 14 and for 
HRQoL item 2).
Convergent validity
The Spearman correlation of the PF total score with 
the JIA core set of outcome variables ranged from 0.5 
to 0.8 (median 0.7). The PF total score best correlation 
was observed with the parent assessment of pain (r = 0.8, 
p < 0.001). For the HRQoL, the median correlation of the 
PhH with the JIA core set of outcome variables ranged 
from 0.6 to 0.8 (median 0.6), whereas for the PsH ranged 
from 0.3 to 0.5 (median 0.4). The PhH showed the best 
correlation with the parent’s assessment of pain (r = 0.8, 
p < 0.001) and the PsH with the parent global assessment 
of well-being (r = 0.6, p < 0.001). The median correla-
tions between the pain VAS, the well-being VAS, and the 
disease activity VAS and the physician-centred and lab-
oratory measures were 0.7 (0.5–0.8), 0.7 (0.5–0.7), 0.7 
(0.5–0.8), respectively.
Discussion
In this study, the Paraguayan Spanish version of the JAMAR 
was cross-culturally adapted from the Spanish version. 
According to the results of the validation analysis, the Para-
guayan Spanish parent and patient versions of the JAMAR 
possess satisfactory psychometric properties. The disease-
specific components of the questionnaire discriminated well 
between patients with JIA and healthy controls. Notably, 
there was no significant difference between the healthy sub-
jects and their affected peers in the school-related problem 
variable. This finding indicates that children with JIA adapt 
well to the consequences of JIA.
Psychometric performances were good for all domains of 
the JAMAR and the overall internal consistency was excel-
lent for all the domains.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core set 
parameters ranged were strong.
The results obtained for the parent version of the JAMAR 
are very similar to those obtained for the child version, 
which suggests that children are equally reliable proxy 
reporters of their disease and health status as their parents. 
Test–retest reliability was not assessed in this patient sam-
ple. The JAMAR is aimed to evaluate the side effects of 
medications and school attendance, which are other dimen-
sions of daily life that were not previously considered by 
other HRQoL tools. This may provide useful information 
for intervention and follow-up in health care.
In conclusion, the Paraguayan Spanish version of the 
JAMAR was found to have satisfactory psychometric prop-
erties and it is, thus, a reliable and valid tool for the multidi-
mensional assessment of children with JIA.
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